Sunday, October 25 edition, released Monday, October 26 with the SANOVO update. Amgen's Imdelltra plus AstraZeneca's Imfinzi extended median survival to 21.1 months from 12.7 in extensive-stage small-cell lung cancer maintenance, while Roche's divarasib beat pooled KRAS G12C comparators. AstraZeneca's Sone-Ve delivered a gastric-cancer survival win beside a missed progression endpoint; SANOVO then showed Tagrisso plus Orpathys improved progression-free survival in untreated, biomarker-selected patients in China. Gilead's $1.275 billion PepStar IL-23 deal and AbbVie's Skyrizi Crohn's approval lead gastroenterology, with hematology, immunology, diagnostics and biotech investment rules rounding out the full Week in Review.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →